Patients with high titres of serum autoantibodies directed against sulphatide may have polyneuropathy syndromes with a prominent sensory component. [1] [2] [3] [4] [5] [6] However, previous studies on a few patients have shown the clinical and electrodiagnostic features of polyneuropathies associated with antisulphatide antibody to be variable. Motor findings may be disabling or absent. Electrodiagnostic studies show predominant axonal loss in some patients, but mainly demyelinating features in others.
In this study, we examined the clinical syndromes and electrodiagnostic data in a large series of 23 patients, collected over five years, with high enzyme linked immunosorbent assay (ELISA) titres (> 4500) of serum IgM antisulphatide antibodies. In the 19 patients with polyneuropathies we considered whether the clinical and electrodiagnostic findings correlated with the results of testing for serum M proteins. We also used immunocytochemistry to evaluate the patterns of serum IgM binding to peripheral nerve.
Methods

PATIENT SELECTION
We reviewed the results of antisulphatide antibody ELISAs in about 20 000 serum samples that were referred to the Neuromuscular Clinical Laboratory, Washington University, St Louis from 1990 to the end of 1994. We found 1 12 serum samples with high titre selective IgM antibody binding to sulphatide (> 4500). These serum samples had no binding to myelin associated glycoprotein (MAG) by ELISA or western blot analysis, and levels of IgM binding to GM1, asialo-GM1, and GDlb gangliosides and to histone H3 that were less than 25% of the antisulphatide titre.7
Detailed histories and neurological examinations and testing for a serum M protein (by either immunoelectrophoresis or immunofixation) were available for 23 of these patients. Twenty of the 23 patients were evaluated by one of us. The three remaining patients were evaluated as part of one of our previous stud- ipids in addition to sulphatide) were excluded from consideration. The clinical and pathological features of antisulphatide antibody associated neuropathies fell into two subgroups according to whether or not a serum M protein was present. Patients with antisulphatide antibodies but no serum M protein typically had axonal, predominantly sensory, syndromes with dysaesthesiae. The pain was disabling in several patients. It could be diffuse or proximal, as well as distal. Weakness was never severe, and only present in a minority of patients. Sensory loss usually involved both large and small fibre modalities, including pain and vibration. Deep tendon reflexes were often preserved even at the ankles. Electrodiagnostic studies showed normal nerve conduction velocities. Reduced amplitudes of sensory nerve action potentials were the predominant abnormality in most studies.
The axonal features of the neuropathy on electrodiagnostic testing correlated with the presence of serum antibodies directed against axons in peripheral nerve. Serum samples from nine of the 10 patients without an M protein showed IgM binding to axons. Blocking experiments suggest that the antisulphatide antibodies are responsible for the binding to axons (G Lopate, unpublished data). However, it is unclear whether the antigenic target on axons is sulphatide, or a structurally similar molecule such as another sulphated glycolipid or glycoprotein.'l 2 11 The second group of patients, with both antisulphatide antibodies and serum IgM M proteins, had prominent motor involvement with significantly smaller CMAP amplitudes on electrodiagnostic testing, and a trend toward more frequent weakness on examination. Weakness was predominantly distal, but in severe cases involved proximal muscles as well. Sensory loss involved both large and small fibre modalities, but, by contrast with patients without an M protein, pain was rarely a prominent complaint. Deep tendon reflexes were often absent, even at proximal sites.
Demyelinating features were common on electrodiagnostic studies of patients with both antisulphatide antibodies and serum IgM M proteins. They were present in 80% of those tested. Prolonged distal latencies and slowed nerve conduction velocities that did not vary greatly from nerve to nerve were the most striking demyelinating feature on electrodiagnostic studies. Conduction block was rarely present.
This pattern of electrodiagnostic abnormalities, prolonged distal latencies, and slow conduction velocities without conduction block, is more similar to that found in anti-MAG neuropathies, than to abnormalities in chronic immune demyelinating polyneuropathy. [12] [13] [14] [15] The electrodiagnostic studies of patients with antisulphatide antibodies but no serum M proteins were significantly different, with no demyelinating features in any of the nine (table  2) .
Some patients with demyelinating features on electrodiagnostic testing had serum IgM binding to peripheral nerve myelin and Schwann cell cytoplasm. However, in several others, serum IgM bound predominantly to endoneurial cells, endoneurium, or axons. The antigenic targets for the IgM in antisulphatide serum samples, that predispose to axonal loss or demyelination in peripheral nerve, remain to be defined. The different patterns of immunostaining of peripheral nerve by serum samples with antisulphatide antibodies suggest that tissue binding of these antibodies is likely to be determined by cross reactivity with other antigens or subfractions of sulphatide. Both axons and myelin contain sulphatide and various other glycoproteins and glycolipids with sulphated sugar moieties." 1617 Other results from our laboratory show that IgM antisulphatide autoantibodies vary greatly in their ability to bind to sulphatide subfractions that vary in the structure and degree of hydroxylation of their lipid moiety. Differences in the range of binding of IgM to such antigenic targets could determine whether the primary focus of an antisulphatide antibody related polyneuropathy is axonal or demyelinating.
